News

Recap: Exelixis Q2 Earnings
9 Aug 22
Earnings
Exelixis Q2 EPS $0.28 Beats $0.19 Estimate, Sales $419.43M Beat $390.91M Estimate
9 Aug 22
Earnings, News
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
9 Aug 22
Biotech, Earnings, Government, News, Penny Stocks, Health Care, Financing, Offerings, Contracts, Small Cap, FDA, Movers, Trading Ideas, General
Earnings Scheduled For August 9, 2022
9 Aug 22
Earnings, News, Pre-Market Outlook, Markets
Piper Sandler Maintains Overweight on Exelixis, Raises Price Target to $32
26 Jul 22
News, Price Target, Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $23
15 Jul 22
News, Price Target, Analyst Ratings
Exelixis Says Cabozantinib In Combination With Nivolumab And Ipilimumab Improved Progression-Free Survival In Phase 3 COSMIC-313 Pivotal Trial In Patients With Previously Untreated Advanced Kidney Cancer
11 Jul 22
News, FDA
The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill
7 Jul 22
Biotech, M&A, News, Penny Stocks, Health Care, Rumors, Contracts, Small Cap, FDA, Insider Trades, Stock Split, Movers, Trading Ideas, General
Exelixis to Pay Ryvu an Upfront Fee of $3M in Exchange for Certain Rights to Ryvu's Sting Agonist Small Molecules
7 Jul 22
News
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022
24 Jun 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
BMO Capital Initiates Coverage On Exelixis with Outperform Rating, Announces Price Target of $28
24 Jun 22
News, Price Target, Initiation, Analyst Ratings
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
21 Jun 22
Biotech, News, Penny Stocks, Health Care, Small Cap, FDA, General
Exelixis Announces Initiation Of STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 In Patients With Metastatic Colorectal Cancer
21 Jun 22
News, FDA
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
16 Jun 22
Biotech, Large Cap, News, Penny Stocks, Health Care, Financing, Offerings, Small Cap, FDA, Insider Trades, Movers, Trading Ideas, General
Exelixis-BioInvent Establish Immuno-Oncology Pact
16 Jun 22
Biotech, News, Penny Stocks, Health Care, Contracts, General
Exelixis and BioInvent Anounced Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
16 Jun 22
News
Exelixis Announces Results From Phase 2 Trial Of Cabozantinib In Combination With Pembrolizumab In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma At ASCO 2022
26 May 22
News, FDA
12 Health Care Stocks Moving In Thursday's Intraday Session
19 May 22
Movers
Press releases
Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update
9 Aug 22
Press Releases
Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
26 Jul 22
Press Releases
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer
11 Jul 22
Press Releases
Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies
7 Jul 22
Press Releases
Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference
5 Jul 22
Press Releases
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer
21 Jun 22
Press Releases
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
16 Jun 22
Press Releases
Better Therapeutics Appoints Frank Karbe as Chief Executive Officer
7 Jun 22
Press Releases
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June
31 May 22
Press Releases
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
26 May 22
Press Releases
Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022
26 May 22
Press Releases